Medtronic Expands AI Footprint in Stroke Care with Brainomix Partnership

Medtronic, a leading medical technology company, has announced a strategic partnership with Brainomix to accelerate the adoption of artificial intelligence (AI) in stroke care across Western Europe. This collaboration marks another significant step in Medtronic's growing commitment to AI-driven healthcare solutions.

Brainomix's AI-Powered Stroke Assessment Tool

The partnership centers around Brainomix's 360 Stroke platform, an AI-powered tool designed to analyze CT brain scans rapidly. The platform utilizes advanced algorithms to detect acute ischemic stroke, identify large vessel blockages, and assess brain tissue status. By expediting the decision-making process in stroke cases, the technology aims to improve patient outcomes through faster identification of appropriate interventions.

Brainomix's AI solution has garnered significant recognition in the medical community. The UK National Institute for Health and Care Excellence (NICE) recently recommended the platform to support clinical decision-making, positioning it as one of only three AI tools to receive such an endorsement out of 13 evaluated.

Clinical Evidence and Impact

A large-scale analysis involving 70,600 stroke patients in the UK has provided compelling evidence of the 360 Stroke platform's benefits. The study revealed an increase in patients referred for mechanical thrombectomy, a crucial clot-removal procedure. Notably, nearly two-thirds of clinicians reported that the introduction of the platform enhanced their ability to identify patients eligible for this treatment.

Medtronic's Strategic AI Initiatives

This partnership with Brainomix aligns with Medtronic's broader strategy to integrate AI across its product portfolio. In November, the company entered into a collaboration with Tempus to explore the use of AI in identifying candidates for interventions such as transcatheter aortic valve replacement (TAVR).

Medtronic's focus on AI-driven solutions comes at a time when its neurovascular business is experiencing growth, particularly in hemorrhagic stroke products outside of China. The company has highlighted the continued acceptance and growth of its Solitaire X revascularization device for acute ischemic stroke treatment as a key factor in shaping its neuroscience business moving forward.